IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0782989
(2010-05-19)
|
등록번호 |
US-8439868
(2013-05-14)
|
우선권정보 |
DE-102 14 847 (2002-09-20) |
발명자
/ 주소 |
- Speck, Ulrich
- Scheller, Bruno
|
출원인 / 주소 |
|
대리인 / 주소 |
Millen, White, Zelano & Branigan, P.C.
|
인용정보 |
피인용 횟수 :
25 인용 특허 :
202 |
초록
▼
The present disclosure relates to balloon catheter medical devices. Some balloon catheter medical devices may include a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried. The dried paclitaxel may be immediately releasable after coming int
The present disclosure relates to balloon catheter medical devices. Some balloon catheter medical devices may include a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried. The dried paclitaxel may be immediately releasable after coming into contact with tissue. Other balloon catheter medical devices may include a balloon surface having a lipophilic proliferation inhibitor, an inflammation inhibitor, or an antioxidant adhered thereto.
대표청구항
▼
1. A balloon catheter medical device comprising: a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried,wherein the dried paclitaxel is immediately releasable after coming into contact with tissue. 2. The medical device according to claim 1,
1. A balloon catheter medical device comprising: a balloon surface having paclitaxel embedded in a low-molecular weight matrix substance adhered thereto and dried,wherein the dried paclitaxel is immediately releasable after coming into contact with tissue. 2. The medical device according to claim 1, wherein said low-molecular weight matrix substance has a molecular weight of less than 5000 D and is selected from contrast agents and dyes used in vivo, sugars, sugar alcohols, low-molecular polyethylene glycols, and biocompatible organic and inorganic salts. 3. The medical device according to claim 1, wherein said low-molecular weight matrix substance is selected from iodinated X-ray contrast agents, paramagnetic chelates, indocyanine green, fluorescein, and methylene blue. 4. The medical device according to claim 1, wherein said low-molecular weight matrix substance is a readily water-soluble hydrophilic matrix substance. 5. The medical device according to claim 1, wherein the low-molecular weight matrix substance has a molecular weight of less than 5000 D. 6. The medical device according to claim 1, wherein the lowe-molecular weight matrix substance has a molecular weight of less than 2000 D. 7. The medical device according to claim 1, wherein said balloon catheter medical device further comprises a stent. 8. The medical device according to claim 1, wherein the balloon catheter medical device does not comprise a stent. 9. The medical device according to claim 1, wherein the balloon surface has preformed longitudinal folds maintaining an inclination to refold after inflation. 10. The medical device according to claim 9, wherein at least an area covered by the folds is covered with the paclitaxel. 11. The medical device according to claim 9, wherein only an area covered by the folds is covered with the paclitaxel. 12. The medical device according to claim 1, wherein the balloon surface consists of a very smooth material to which the paclitaxel embedded in the low-molecular weight matrix substance adheres sufficiently well to resist forces required for folding, essentially without damage. 13. The medical device according to claim 1, wherein the balloon surface is coated by immersion in a low-viscosity pacitaxel solution while in a fully folded condition. 14. The medical device according to claim 1, wherein the paclitaxel is present as a dry solid on the balloon surface. 15. The medical device according to claim 14, wherein an effective dose of the paclitaxel includes amorphous structures with particle sizes ranging from <0.1 micron to 5 microns that dissolve quickly due to their large surface area and despite the poor water-solubility of the paclitaxel. 16. The medical device according to claim 1, wherein matrix the low-molecular weight matrix substance is hydrophilic. 17. The medical device according to claim 1, wherein the paclitaxel is applied to the balloon surface with said low-molecular weight matrix substance. 18. The medical device according to claim 1, wherein the balloon surface further comprises a substance that influences the gliding quality of the device or that prevents blood coagulation. 19. A balloon catheter medical device comprising: a balloon surface having a lipophilic proliferation inhibitor, a lipophilic inflammation inhibitor, or a lipophilic antioxidant adhered thereto, wherein the lipophilic proliferation inhibitor, the lipophilic inflammation inhibitor, or the lipophilic antioxidant is embedded in a low-molecular weight matrix substance, applied thereon to the balloon surface and dried, andwherein the dried lipophilic proliferation inhibitor, the dried lipophilic inflammation inhibitor, or the dried lipophilic antioxidant is immediately releasable after coming into contact with tissue. 20. The medical device according to claim 19, wherein said the lipophilic proliferation inhibitor, the lipophilic inflammation inhibitor, or the lipophilic antioxidant is selected from taxanes, Rapamycin, tacrolimus, corticoids, sexual hormones, statins, epothilones, probucol, prostacyclins, and angiogenesis inducers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.